Adrian Morris

Adrian is Chief Development Officer at jCyte, a clinical stage biotech company dedicated to preserving and restoring vision in patients with degenerative retinal disorders. Its lead product jCell is a first in class allogeneic cell therapy in late-stage clinical development for retinitis pigmentosa.

Adrian has three decades of experience as a pharmaceutical executive and has spent the majority of his career in senior global positions at GlaxoSmithkline, guiding development programs and launching new products in multiple therapy areas, including the first combination therapy for HIV, the first influenza anti-viral, the first long-acting beta agonist for asthma and many more.

He has also previously led GSKs molecular diagnostics division, headed business development for Europe, and led the company’s global response to the H1N1 influenza pandemic, leading a team working with governments worldwide to ensure their preparedness, through the provision of vaccines and antivirals.

Before joining the pharmaceutical industry, he spent his early career researching and publishing on the genetic basis of inherited human diseases at Guy’s Hospital in London. Adrian is a geneticist by training and earned his Master’s degree in Genetics from Cambridge University, UK.